Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Healthy
Interventions: Active Dronabinol, Active Pregnenolone, Placebo Dronabinol, Placebo Pregnenolone; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Type 2 Diabetes Mellitus
Interventions: Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant, conjugated linoleic acid (CLA); Drug · Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anxiety Disorders
Interventions: SSR149415, Placebo, Paroxetine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Severe Hypertriglyceridemia
Interventions: AKR-963; Drug
Lead sponsor: Trygg Pharma, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Celiac Disease
Interventions: larazotide acetate, placebo; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Orange, California • San Francisco, California • Torrington, Connecticut + 17 more

Conditions: Type1 Diabetes
Interventions: 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule; Drug
Lead sponsor: Immunomolecular Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chula Vista, California • Aurora, Colorado • Renton, Washington

Conditions: Dental Pain
Interventions: XPF-001, placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Menopause
Interventions: Ashoka Bark and Shatavari, Placebo; Dietary Supplement · Other
Lead sponsor: Vidya USA Corporation; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Breastfeeding
Interventions: Moringa leaf powder, Placebo; Dietary Supplement · Other
Lead sponsor: University of Kentucky; Other
Eligibility: 0 Months and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Femoroacetabular Impingement
Interventions: Fisetin, Placebo; Drug
Lead sponsor: Steadman Philippon Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Vail, Colorado

Conditions: Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions: LFF269, Placebo to LFF269; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions: Famotidine, Celecoxib, Placebo; Drug
Lead sponsor: Leidos Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more

Conditions: Essential Hypertension
Interventions: LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, glimepiride, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 102
States / cities: Concord, California • Escondido, California • Fullerton, California + 83 more

Conditions: Transient Insomnia
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 5
States / cities: Glendale, California • San Diego, California • Overland Park, Kansas + 1 more

Conditions: Myelogenous Leukemia, Chronic
Interventions: nilotinib, imatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 31
States / cities: Los Angeles, California • San Diego, California • Vallejo, California + 27 more

Conditions: Hyponatremia With Normal Extracellular Fluid Volume
Interventions: lixivaptan, placebo; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 38
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Ifetroban Sodium, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: La Mesa, California • San Francisco, California • Farmington, Connecticut + 17 more

Conditions: Alcohol Dependence
Interventions: Zonisamide, Take Control, Placebo (for Zonisamide); Drug · Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 21 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PreDiabetes
Interventions: Low-dose bitter melon, High-dose bitter melon, Placebo; Dietary Supplement
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 74 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Miami Gardens, Florida • Port Saint Lucie, Florida • Addison, Illinois

Conditions: Uterine Fibroids
Interventions: Proellex, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more

Conditions: Postoperative Delirium
Interventions: Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 65 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Major Depressive Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 30
States / cities: Birmingham, Alabama • Cerritos, California • Encino, California + 27 more

Conditions: Post-traumatic Stress Disorder
Interventions: Sertraline, Placebo oral capsule; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus

An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Satavari and Ashoka for Menopause (SAM) Study

Moringa Supplementation for Improved Milk Output

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism

Effects of Bitter Melon on Cardiometabolic Health

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims